Dr Rubio is a clinical neurologist focused, since 2010, on neuromuscular disorders, especially in ALS and other motor neuron diseases. Aside from his clinical activity coordinating the ALS Multidisciplinary Unit, his efforts are centered on both clinical and basic research, the latter including works on mouse models (SOD1 G93A mouse) and the search for disease biomarkers in human tissue samples, in collaboration with the Group of Neuroplasticity and Regeneration (Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Autònoma de Barcelona).
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of ALS but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.